Gilead Unveils 'Remarkable Outcomes' From Late-Stage Lenacapavir Study Showing Promise In Preventing HIV Infections
Gilead Sciences Inc · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · Now $131.10
+3.0% in 7d after detection
Post-detection moves
1h
—
1d
+0.1%
3d
+3.0%
7d
+3.0%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS